The following immune markers were examined to determine whether LSH or SSH is more representative of the original tumor and which better indicates patient prognosis: CD4 in LSH (CD4LSH), CD4 in SSH (CD4SSH), CD8 in LSH (CD8LSH), CD8 in SSH (CD8SSH), CD15 in LSH (CD15LSH), CD15 in SSH (CD15SSH), CD20 in LSH (CD20LSH), CD20 in SSH (CD20SSH), CD56 in LSH (CD56LSH), and CD56 in SSH (CD56SSH). The gene discussed is NCAM1; the disease is neoplasm.